Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants—translating clinical trial data into practice

Journal of Interventional Cardiac Electrophysiology

Volumn 40, Issue 3, 2014, Pages 261-268

  Ezekowitz, Michael D ^a,c   Spahr, Judy ^b   Ghosh, Pradeepto ^b   Corelli, Kathryn ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

Anticoagulants; Arrhythmia; Atrial fibrillation; Stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPARATIVE STUDY; COMPLICATION; HUMAN; ORAL DRUG ADMINISTRATION; STROKE; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FACTOR XA INHIBITORS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; STROKE; THIAZOLES; THIOPHENES; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84929997880     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-014-9893-z     Document Type: Article

References (33)

1. Petersen, P., Boysen, G., Godtfredsen, J., Andersen, E. D., & Andersen, B. (1989). Placebo controlled, normalized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet, 1, 175–179.
2. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. (1990). The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. New England Journal of Medicine, 323, 1505–1511.
3. Stroke Prevention in Atrial Fibrillation Investigators. (1991). Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation, 84, 527–539.
4. Ezekowitz, M. D., Bridgers, S. L., James, K. E., Carliner, N. H., Colling, C. L., Gornick, C. C., et al. (1992). Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. New England Journal of Medicine, 327, 1406–1412.
5. EAFT (European Atrial Fibrillation Trial) Study Group. (1993). Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet, 342, 1255–1262.
6. The ACTIVE Investigators. (2009). Effect of clopidogrel added to aspirin in patients with atrial fibrillation. New England Journal of Medicine, 360, 2066–2078.
7. Block, P. C., Burstein, S., Casale, P. N., Kramer, P. H., Teirstein, P., Williams, D. O., et al. (2009). Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC. Cardiovascular Interventions, 2, 594–600.
8. Holmes, D. R., Reddy, V. Y., Turi, Z. G., Doshi, S. K., Sievert, H., Buchbinder, M., et al. (2009). Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized noninferiority trial. Lancet, 374, 534–542.
9. Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H. C., Hart, R., Golitsyn, S., et al. (2011). Apixaban in patients with atrial fibrillation. New England Journal of Medicine, 364, 806–817.
10. Mant, J., Hobbs, F. D., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., et al. (2007). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (The Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet, 370(9586), 493–503.
11. ACTIVE Writing Group on behalf of the ACTIVE Investigators. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 367, 1903–1912.
12. Olsson, S. B., & Executive Steering Committee of the SPORTIF III Investigators. (2003). Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet, 362(9397), 1691–1698.
13. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. (2005). Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Journal of the American Medical Association, 293, 690–698.
14. Ezekowitz, M. D., Reilly, P. A., Nehmiz, G., Simmers, T. A., Nagarakanti, R., Parcham-Azad, K., et al. (2007). Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). American Journal of Cardiology, 100, 1419–1426.
15. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., RE-LY Steering Committee and Investigators, et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361, 1139–1151. Erratum in: (2010). New England Journal of Medicine,363(19),1877.
16. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010). Newly identified events in the RE-LY trial. (Letter). New England Journal of Medicine, 363, 1875–1876.
17. Ezekowitz, M. D., Wallentin, L., Connolly, S. J., Parekh, A., Chernick, M. R., Pogue, J., et al. (2010). Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation, 122, 2246–2253.
18. Wallentin, L., Yusuf, S., Ezekowitz, M. D., Alings, M., Flather, M., Franzosi, M. G., et al. (2010). Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet, 376, 975–983.
19. Diener, H. C., Connolly, S. J., Ezekowitz, M. D., Wallentin, L., Reilly, P. A., Yang, S., et al. (2010). Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurology, 9(12), 1157–1163. Erratum in: (2011). Lancet Neurology,10 (1), 27.
20. Boehringer Ingelheim dabigatran briefing document. (2010). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf. Accessed 12 Mar 2011.
21. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacker, W., et al. (2011). Rivaroxaban versus warfarin in non valvular atrial fibrillation. New England Journal of Medicine, 365, 883–891.
22. Paikin, J. S., Manolakos, J. J., & Eikelboom, J. W. (2012). Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. Expert Reviews in Cardiovascular Therapy, 10, 965–972.
23. Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., et al. (2011). Apixaban in patients with atrial fibrillation. New England Journal of Medicine, 365, 981–992.
24. Eliquis © (apixaban) (2012) tablets [prescribing information]. Princeton, NJ; Bristol Myers Squibb Co.
25. Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., et al. (2013). Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 369(22), 2093–2104. doi:10.1056/NEJMoa1310907. Epub 2013 Nov 19.
26. Ellis, D. J., Usman, M. H., Milner, P. G., Canafax, D. M., & Ezekowitz, M. D. (2009). The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation, 120, 1029–1035.
27. © (dabigatran etixilate mesylate) (2010) capsules [prescribing information]. Ridgefield CT: Boehringer Ingelheim Pharmaceuticals Inc.
28. Xarelto © (rivaroxaban) (2013) tablets [prescribing information]. Titusville, NJ; Janssen Pharmaceuticals, Inc. (revised).
29. Daiichi Sankyo Submits SAVAYSA(TM) (edoxaban) Tablets New Drug Application to the U.S. FDA for once-daily use for stroke risk reduction in atrial fibrillation and for the treatment and prevention of recurrence of venous thromboembolism. http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006065.html
30. Mueck, W., Schwers, S., & Stampfuss, J. (2013). Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations, and relevance of coagulation monitoring. Thrombosis Journal. doi:10.1186/1477-9650-11-10.
31. Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., et al. (2008). Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest, 133(6 Suppl), 546S–592S.
32. Nagarakanti, R., Ezekowitz, M. D., Oldgren, J., Yang, S., Chernick, M., Aikens, T. H., et al. (2011). Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation, 123, 131–136.
33. Piccini, J. P., Stevens, S. R., Lokhnygina, Y., Patel, M. R., Halperin, J. L., Singer, D. E., et al. (2013). Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. Journal of the American College of Cardiology, 61, 1998–2006.